

## Antimicrobial Properties of Newly Synthesized Derivatives of Coumarine

S. Govori, S. Spahiu, V. Kalaj, O.Leci,  
A. Haziri and H. Ibrahim

<sup>1</sup>Department of Chemistry, Section of Organic and Biochemistry,  
Faculty of Natural Science, University of Prishtina,  
“Mother Teresa” Street 5, 10000 Prishtina, Republic of Kosova

**Abstract: Problem statement:** Coumarins are well known for their biological activity. On the basis of that we have synthesized some new derivatives of coumarine and investigated their antimicrobial properties. **Approach:** 4-Heteroaryl-coumarin-3-carbaldehydes 4(a-d) are synthesized by condensation of 4-chloro-coumarin-3-carbaldehydes 2 and corresponding heteroaryl amines 3(a-d) under reflux reaction conditions. Antimicrobial properties of new coumarins 4(a-d) are investigated and results are submitted for their activities against *Staphylococcus aureus*, *Escherichia coli*, *Hafnia alvei*, *Pseudomonas aeruginosa* and *Enterobacter cloacae*. Applying the Agar disc diffusion technique we measured diameters of the inhibition zone around discs which are previously wetted with N, N-DMF solution of compounds, 1, 3 and 5 mg L<sup>-1</sup>. **Results:** The inhibition zone depends from concentrations and also from sort of bacteria. The inhibition zone differ from 0 to 30mm. Two sort of bacteria, *Hafnia alvei* and *Pseudomonas aeruginosa*, are resistant to these new synthesized compounds. **Conclusion:** From results we may conclude that these derivatives showed moderate to high activity against *Staphylococcus aureus*, *Escherichia coli* and *Enterobacter cloaco*. Compounds 4(a-d) are more active against *Staphylococcus aureus*, *E.coli* and *Enterobacter cloaco*. Compounds 4(a-d) are not active against *Hafnia alvei* and *Pseudomonas aeruginosa*.

**Key words:** Coumarine Derivatives, Antimicrobial properties, *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Escherichia coli*, *Enterobacter cloacae*, *Hafnia alvei*

### INTRODUCTION

Although coumarins have been known for many years, the researche about their properties such as anticoagulant (Garazd *et al.*, 2005; Katritzky *et al.*, 1996; Manolov and Danchev, 1995), antibacterial (Arora and Mathur, 1963), antiinflammatory (Al-Haiza *et al.*, 2003), antioxidant, activities has become duty and responsibility for researchers to discover new methods of synthesizing new biological active coumarins.

In the course of our studies on the chemistry of coumarins and related structures (Haber *et al.*, 1995; Govori *et al.*, 2002), we have investigated reactions for the preparation of 4-heteroaryl-coumarin-3-carbaldehyde from 4-chlorocoumarin-3-carbaldehyde with different heteroaryl amines. Antibacterial activities of new coumarine derivatives were tested *in vitro* against bacterial strains; *Staphylococcus aureus*, *Escherichia coli*, *Hafnia alvei*, *Pseudomonas aeruginosa* and *Enterobacter cloacae* (Philip *et al.*, 2009; Azadeh and

Meon, 2009; Ghanbarpour *et al.*, 2010; Rusli *et al.*, 2009) by Agar disc diffusion technique.

### MATERIALS AND METHODS

Melting points were determined with a Buechi apparatus. The IR spectra were recorded for KBr pellets with a Perkin Elmer 1725×FT IR spectrophotometer, <sup>1</sup>H-NMR spectra were recorded on a Bruker AC 300 (300MHz) spectrometer with TMS as internal standard. Elemental analyses were performed in “Ruder Boskovic” Institute, Croatia.

**General procedure for preparation of 4-heteroaryl-coumarin-3-carbaldehydes 4(a-d):** The solution of 4-chlorocoumarin-3-carbaldehyde 2 (0.5g, 24 mmol) and of appropriate heteroarylamine 3(a-d) (24mmol), in acetonitrile (30 mL) in presence of catalytical amount of triethylamine was refluxed for 2-4 h. After cooling the mixture was filtered off, washed with acetonitrile and recrystallised.

**Corresponding Author:** S. Govori, Section of Organic and Biochemistry, Department of Chemistry, Faculty of Natural Science, University of Prishtina, “Mother Teresa” Street 5, 10000 Prishtina, Republic of Kosova

**4-(4,6-dichloropyrimidin-2-ylamino)-coumarin-3-carbaldehyde (4a):** Yield: 45.85%, m.p. 280 °C from mixture ethanol: DMF (3:1) IR (KBr)  $\text{cm}^{-1}$ : 3350 (N-H), 3120 (C-H arom), 1734-1664 (C = O, CHO;  $\alpha$ -pir.); 1610 (C = N); 1528-1420 (C=C arom.), 758 (C-C arom).  $^1\text{H-RBM}(\text{CDCl}_3)$  (ppm): 9-9.10 s (1H;CHO); 8.42-6.46 m (5H;arom), 3.92 s (1H;N-H),  $^{13}\text{C-RBM}$  (DMSO- $d_6$ ) (ppm): CHO(179.30); C-NH(163.14); C-Cl(161.57); C=O (159.65); C arom.(154.19- 104.01); DMSO (40.34-34.43). Anal: Calculated for  $\text{C}_{13}\text{H}_6\text{N}_4$ : (C, 59.99%), (H, 2.75%), (N, 12.44%) Found: (C, 60.00%), (H, 2.90%), (N, 12.38%).

**4-(2-chloro-6,7-dimethoxyquinazolin-4-ylamino)-coumarin-3-carbaldehyde (4b):** Yield: 43,87%, m.p. 300°C from ethanol: DMF (3:1). IR (KBr)  $\text{cm}^{-1}$ : 3305-3122 (N-H), 3001 (C-H arom), 3483-3122 (N-H), 3001 (C-H arom), 2920 (C-H al), 1648 (C = O), 1624 (C = N), 1516-1417 (C = C arom).  $^1\text{H-RBM}(\text{CDCl}_3)$  (ppm): 9.60 s (1H;CHO); 8.03-6.74 m (7H;ar.); 4.24 s (1H;N-H); 5.63-5.27 ss (6H;2OCH<sub>3</sub>). Anal: Calculated for  $\text{C}_{22}\text{H}_{20}\text{N}_3$ : (C, 59.80%), (H, 4.56%), (N, 9.51 %) Found: (C, 60.00%), (H, 4.29%), (N, 9.44%).

**4-(5-bromotiazol-2-ylamino)-coumarin-3-carbaldehyde (4c):** Yield: 51.19%. m.p. 298°C from acetic acid. IR (KBr)  $\text{cm}^{-1}$ : 3350 (N-H), 1735-1702 (C = O, CHO) 1654 (C = N), 1560-1458 (C = C arom).  $^1\text{H-RBM}(\text{CDCl}_3)$  (ppm): 9.32 sd (1H;CHO); 8.49-6.08 m (5H;arom); 3.69-3.33 d (1H;NH). Anal: Calculated for  $\text{C}_{14}\text{H}_{10}\text{N}_2$ : (C, 45.92%), (H, 2.75%), (N, 7.65%). Found: (C, 45.27%), (H, 2.97%), (N, 7.80%).

**4-(2-chloropyridin-3-ylamino)-coumarin-3-carbaldehyde (4d):** Yield: 54%, m.p. 215°C from ethanol. IR (KBr)  $\text{cm}^{-1}$ : 3330(N-H), 3055 (C-H arom), 1735 (C=O, CHO;  $\alpha$ -piron), 1610 (C = N) 1508-1458 (C=C aromatic).  $^1\text{H-RBM}(\text{CDCl}_3)$  (ppm): 9.32 sd (1H;CHO); 8.49-6.08 m (5H;arom); 3.69-3.33 d (1H;NH). Anal: Calculated for  $\text{C}_{16}\text{H}_{12}\text{N}_2$ : (C, 60.87%), (H, 3.83%), (N, 8.87%). Found: (C, 60.04%), (H, 3.75%), (N, 8.80%).

The antimicrobial activity of compounds 4(a-d) was determined by Agar disc diffusion technique. Coumarin samples were tested *in vitro* against bacterial strains; *Staphylococcus aureus*, *Escherichia coli*, *Hafnia alvei*, *Pseudomonas aeruginosa* and *Enterobacter cloaco*, were incubated at 37°C during a period 24 hrs and the inhibition zones were measured. The compounds were tested at three different concentrations, 1, 3 and 5 mg  $\text{mL}^{-1}$  in DMF.

## RESULTS

Nucleophilic substitution of 4-chloro-coumarin-3-carbaldehyde (2) by corresponding aromatic amines 3(a-d), has given the corresponding 4- heteroaryl-amino-coumarin-3-carbaldehydes 4(a-d) in good yields.

The structure of synthesized coumarins 4(a-d) were determined from IR,  $^1\text{H-NMR}$ ,  $^{13}\text{C-NMR}$  spectra and elementary analysis (Fig. 1).




Fig. 1: Structure of Coumarine derivatives 4 (a-d)

Table 1: Microbiological activity of newly synthesized coumarin derivatives

Test compound	Concentration	<i>E.Coli</i> ATCC ® 25922	<i>S.Aureus</i> ATCC ® 25923	<i>Pseudomonas</i> <i>aeruginosa</i> ATCC ® 27853	<i>Hafnia alvei</i> PTCC® 2005	<i>Enterococcus</i> <i>cloacae</i> PTCC ® 2005
4a	1	17	23	0	0	17
	3	17	23	0	0	18
	5	27	27	0	0	18
4b	1	20	22	0	0	22
	3	20	25	0	0	20
	5	20	30	0	0	15
4c	1	0	29	0	0	10
	3	15	27	0	0	15
	5	18	20	0	0	17
4d	1	20	0	0	0	18
	3	20	0	0	0	0
	5	23	0	0	0	0




Fig. 2: Graphs of microbiological activity results for compounds 4(a-d)

Continuation to our study we examined the antimicrobial activity of synthesized compounds 4(a-d). Our investigation is directed toward their activity against *Staphylococcus aureus*, *Escherichia coli*, *Hafnia alvei*, *Pseudomonas aeruginosa* and *Enterobacter cloaco*. Applying the disc method we have measured diameters of the inhibition zones around disc which are previously wetted with DMF solution of the samples examined (1, 3 and 5 mg mL<sup>-1</sup>) were applied (Table 1).

### DISCUSSION

The antimicrobial activity of synthesized coumarins is shown in Table 1 presented with graph (Fig. 2). From the results, we saw that new synthesized coumarins 4(a-d) show antibacterial activity against some bacteria. Compound **4a** show activity against three bacteria, *E. coli*, *S.Aureus* and *E. Cloaco*. We found that if we increase the concentration of

compound 4a the diameter of inhibition zone will not increase as we have expected. The Compound 4a don't show any activity against the *P. Aeruginosa* and *H. alvei*. Compound 4b show activity against *E. coli*, *S.Aureus* and *E. Cloaco*, but in the case of *E. coli* and *E. Cloaco*, if we increase the concentration of compound 4b, the activity will not change. But to the *S. Aureus*, if we increase concentration the inhibition zone will increase. Coumarine derivative 4c show antibacterial activity but in case of *S. Aureus* if we increase concentration of compound 4c, the activity of this compound will decrease. Compound 4d show activity against *E. coli* and also in the concentration of 1mg L<sup>-1</sup> show activity against *E. Cloaco*. If we increase concentration the activity is zero against *E. Cloaco*.

Two bacteria, *P. Aureiginosa* and *H. Alevei* are resistant to all this compounds and also they are resistant to all this three different concentrations.

## CONCLUSION

From results we may conclude that these coumarin derivatives were shown moderate to high activity against *Staphylococcus aureus*, *Escherichia coli* and *Enterobacter cloaco*. Compounds 4(a-d) are more active against *Staphylococcus aureus*, *E. coli* and *Enterobacter cloaco*.

Compounds 4(a-d) are not active against *Hafnia alvei* and *Pseudomonas aeruginosa*.

## ACNOWLEDGMENT

The researchers acknowledge the financial support received from the University of Prishtina, Kosova.

## REFERENCES

- Al-Haiza, M.A., M.S. Mostafa and M.Y. El-Kady, 2003. Synthesis and biological evaluation of some new coumarin derivatives. *Molecules*, 8: 275-286. DOI: 10.3390/80200275
- Arora, R.B. and C.N. Mathur, 1963. Relationship between structure and anticoagulant activity of coumarin derivatives. *Brit. J. Pharmacol.*, 20 : 29-35. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1703756/>
- Garazd, Y.L., E.M. Kornienko, L.N. Maloshtan, M.M. Garazd and V.P. Khilya, 2005. Modified coumarins. 17. synthesis and anticoagulant activity of 3,4-cycloannelated coumarin d-glycopyranosides. *Chem. Natural Compounds*, 41: 508-512. DOI: 10.1007/s10600-005-0194-8
- Govori, S., V. Kaljaj, V. Rapic, L. Kaljaj and S. Djakovic, 2002. synthesis and structure of some 3, 4-annelated coumarin systems. *Heterocycl. Commun.*, 8: 129-134.
- Heber, D., I.C. Ivanov and S.K. Karagiosov, 1995. The vilsmeier reaction in the synthesis of 3-substituted [1]benzopyrano [4,3-b]pyridine-5-ones. an unusual pyridine ring closure. *J. Heterocycl. Chem.*, 32: 505-509. DOI: 10.1002/jhet.5570320221
- Manolov, I. and N.D. Danchev, 1995. Synthesis, toxicological and pharmacological assessment of some 4-hydroxycoumarin derivatives. *Eur. J. Med. Chem. Chim.*, 30: 531-536. DOI: 10.1016/0223-5234(96)88266-3
- Katritzky, A.R., 1996. In *Comprehensive Heterocyclic Chemistry*. 1st Edn., Elsevier Science and Technology, ISBN: 0080420729, pp: 11628.
- Philip, K., N.A. Malek, W. Sani, S.K. Shin and S. Kumar *et al.*, 2009. Antimicrobial activity of some medicinal plants from Malaysia. *Am. J. Applied Sci.*, 6: 1613-1617. DOI: 10.3844/ajassp.2009.1613.1617.
- Azadeh, B.F. and S. Meon, 2009. Molecular characterization of *Pseudomonas aeruginosa* UPM P3 from oil palm rhizosphere. *Am. J. Applied Sci.*, 6: 1915-1919. DOI: 10.3844/ajassp.2009.1915.1919
- Ghanbarpour, R., M. Salehi, R. Ghanbarpour and M. Salehi, 2010. Determination of adhesin encoding genes in *Escherichia coli* isolates from omphalitis of chicks. *Am. J. Anim. Veter. Sci.*, 5: 91-96. DOI: 10.3844/ajavsp.2010.91.96
- Rusli, F.M., M.S. Mohamed, R. Mohamad, N.N. Tri Puspaningsih and A. A. Ariff, 2009. Kinetics of xylanase fermentation by recombinant *Escherichia coli* DH5a in shake flask culture. *Am. J. Biochem. Biotechnol.*, 5: 109-117. DOI: 10.3844/ajbbbsp.2009.109.117